Advertisement
Abstract| Volume 21, SUPPLEMENT 3, S151, November 2020

Real-life data of Cabazitaxel-Prednisone second-line scheme in metastatic castration-resistant prostate cancer

Open AccessDOI:https://doi.org/10.1016/S2666-1683(20)36208-X
Real-life data of Cabazitaxel-Prednisone second-line scheme in metastatic castration-resistant prostate cancer
Previous ArticleEarly results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing I line treatment with abiraterone acetate (ARTO trial-NCT03449719)
Next ArticleOncologic results of radical prostatectomy for high-risk prostate cancer and prognostic factors for recurrence and progression-free survival
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S2666-1683(20)36208-X

      Copyright

      © 2020 Elsevier B.V. Published by Elsevier Inc.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX